Navigation Links
Brainlab and SurgiVision Announce Strategic Alliance in MRI-Guided Drug Delivery and Other Interventional MRI Technologies in Neurosurgery

MUNICH, April 11, 2011 /PRNewswire/ -- Brainlab AG and SurgiVision, Inc. today announced a collaboration aimed at integrating SurgiVision's ClearPoint® product line with Brainlab's iMRI product line, with particular focus on local delivery of drugs and other therapeutic agents to precision targets in the brain under magnetic resonance imaging (MRI) guidance.

Brainlab and SurgiVision believe the integration of their technologies will allow patient-specific treatment planning, simplified clinical workflows and optimal delivery of drugs to the brain.  Under the terms of the agreement, Brainlab also received the right to sell SurgiVision's ClearPoint product line, including the right to exclusively sell ClearPoint products in the neurological drug delivery field, and Brainlab made an investment into SurgiVision.  SurgiVision will continue to sell its ClearPoint product line directly for all applications outside the neurological drug delivery field.

SurgiVision's ClearPoint system provides guidance for the placement and operation of instruments during neurological procedures performed within the MRI environment.  Using the ClearPoint system, a physician sees and selects a neurological target, aims SurgiVision's targeting device and watches via MRI as the surgical instrument is advanced to the target and the therapy is delivered.  SurgiVision's ClearPoint system has received both FDA clearance and CE Mark.  SurgiVision also recently received FDA clearance for its SmartFlow™ injection cannula.

Brainlab's Brainsuite® iMRI integrates intra-operative MRI with surgical planning and ceiling-mounted navigation, allowing full utilization of intra-operative data for making informed decisions  during the procedure.  iPlan® Flow enables neurosurgeons to optimize local drug delivery to the CNS, based on patient specific imaging.

"Direct, image-guided delivery of therapeutic agents into the brain provides the next generation platform for delivering a wide range of promising therapies for patients suffering from CNS disorders such as Parkinson's disease and malignant brain tumors," said Dr. Krystof Bankiewicz, Vice Chair and Professor, Department of Neurosurgery and Director of the NeuroTherapeutics Delivery Center at the University of California San Francisco.  "This collaboration between two important players in the field is welcome news to pharmaceutical companies, biotech companies and researchers with therapeutic agents that need to be delivered in a targeted, patient-specific, image-guided fashion."

"MRI guided interventions is an important, emerging area of medicine.  We are excited about the partnership with SurgiVision, the integration of our technologies in functional neurosurgery, and the opportunity to offer these innovative solutions to customers through our global sales network," said Stefan Vilsmeier, CEO of Brainlab.

"We are very pleased to announce this collaboration with Brainlab, a pioneer and leader in image-guided interventions," said Kimble Jenkins, CEO of SurgiVision.  "Together with our new partner, we are excited about providing to clinicians powerful, new capabilities in targeted drug delivery and other MRI-guided therapies to benefit patients who suffer from CNS disorders."

About Brainlab

Brainlab develops, manufactures and markets software-driven medical technology that supports targeted, less-invasive treatment. Brainlab technology drives collaboration between hospitals and clinicians from a wide variety of subspecialties—from neurosurgery and oncology to orthopedics, ENT, CMF and spine & trauma. This integration delivers better access to improved and more efficient treatment. Founded in 1989, the privately held Brainlab group has 5,260 systems installed in over 80 countries. Based in Munich, Germany, Brainlab employs 950 people, including 240 R&D engineers on the product development team, in 16 offices worldwide.

About SurgiVision

Founded in 1998, SurgiVision, Inc. is a leader in the emerging field of MRI-guided interventions, creating innovative platforms for performing the next generation of minimally invasive surgical procedures in the brain and heart.  Utilizing a hospital's existing MRI suite, SurgiVision's FDA-cleared ClearPoint® system is designed to enable a range of minimally invasive procedures in the brain.  In partnership with Siemens Healthcare, SurgiVision is developing the ClearTrace™ system to enable MRI-guided catheter ablations to treat cardiac arrhythmias, including atrial fibrillation. Building on the imaging power of MRI, SurgiVision's interventional platforms strive to improve patient outcomes while reducing procedure costs and times. SurgiVision is also working with Boston Scientific Corporation to incorporate SurgiVision's MRI-safety technologies into Boston Scientific's implantable leads for cardiac and neurological applications.

SOURCE Brainlab
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Brainlab Launches Refreshed Website
2. Medtronic, Stryker, and BrainLAB Covered in New Surgical Navigation Market Research Reports Released by Millennium Research Group
3. Self Regional Healthcare Becomes First in the Southeast to Treat Spine Patients Using Advanced Integrated Operating Room Technology From Brainlab
4. Brainlab Offers Real-Time Monitoring for IGRT
5. Brainlab Collaborates With Toshiba Medical Systems on Integrated Surgical Suite
6. Slovenias Sole Radiotherapy Hospital Unveils Novalis Tx(TM) Platform From Varian and BrainLAB
7. St. Lukes Hospital Acquires Pioneering Technology From BrainLAB
8. Advanced Image-Guided Surgery Technology From BrainLAB Now Available in New York State
9. Avanir Pharmaceuticals Announces Appointment of William Sibold as Chief Commercial Officer
10. Xeridiem™ Medical Devices Announces New Website Launch
11. Lanx®, Inc. Announces 17,000 Aspen™ Spinous Process Fixation Devices Implanted
Post Your Comments:
(Date:12/1/2015)... 01, 2015 ... addition of the "2016 Europe ... E. Coli, Enterovirus, Rhinovirus, Rotavirus, Salmonella, ... their offering. --> ... the "2016 Europe Enteric Disease ...
(Date:12/1/2015)... -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing ... that the company will present at the LD Micro Main ... Luxe Sunset Boulevard Hotel in Los Angeles, CA. ... will present on Thursday, December 3, at 9:00 am Pacific ... register at least 10 minutes prior to the start of ...
(Date:12/1/2015)... CytRx Corporation (NASDAQ: CYTR ), a ... announced that it has reached its enrollment target of ... clinical trial of aldoxorubicin in patients with previously treated ... completed in Q1 2016. The Phase 3 trial is a ... Assessment from the FDA at 79 sites in ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... December 01, 2015 , ... For many X-rays taken ... for accurate interpretation by the radiologist. The marking utensils are so small, however, ... has found a way to alleviate this problem. , He developed the patent-pending ...
(Date:12/1/2015)... ... December 01, 2015 , ... Visage accelerates ... a wholly owned subsidiary of Pro Medicus Ltd. (ASX: PME), has announced they ... Society of North America (RSNA) 2015 annual meeting through December 3 in Chicago, ...
(Date:12/1/2015)... ... December 01, 2015 , ... Next ... selected as a finalist in this year’s Fierce Innovation Awards: Healthcare Edition, an ... was recognized as a finalist in the category of Digital Solutions for its ...
(Date:12/1/2015)... ... ... Lutronic, a leading innovator of aesthetic and medical laser and energy-based technology, announced ... the United States. Clarity is a Superior Dual Wavelength Platform which combines two ... platform that is easy to own and operate. , For over a decade, ...
(Date:12/1/2015)... ... December 01, 2015 , ... PYA’s ... Post-Affiliation Integration ,” addresses a main “pain point” for merging or aligning healthcare ... once a deal is signed. This quick-read guidance suggests that failing to ...
Breaking Medicine News(10 mins):